400647-59-8Relevant articles and documents
A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin
Maass, Katie F.,Kulkarni, Chethana,Quadir, Mohiuddin A.,Hammond, Paula T.,Betts, Alison M.,Wittrup, Karl Dane
, p. 4409 - 4416 (2015)
Standard cell proliferation assays use bulk media drug concentration to ascertain the potency of chemotherapeutic drugs; however, the relevant quantity is clearly the amount of drug actually taken up by the cell. To address this discrepancy, we have devel
A lysosome-targeted drug delivery system based on sorbitol backbone towards efficient cancer therapy
Maniganda, Santhi,Sankar, Vandana,Nair, Jyothi B.,Raghu,Maiti, Kaustabh K.
, p. 6564 - 6569 (2014)
A straightforward synthetic approach was adopted for the construction of a lysosome-targeted drug delivery system (TDDS) using sorbitol scaffold (Sor) linked to octa-guanidine and tetrapeptide GLPG, a peptide substrate of lysosomal cysteine protease, cathepsin B. The main objective was to efficiently deliver the potential anticancer drug, doxorubicin to the target sites, thereby minimizing dose-limiting toxicity. Three TDDS vectors were synthesized viz., DDS1: Sor-GLPG-Fl, DDS2: Sor-Fl (control) and DDS3: Sor-GLPGC-SMCC-Dox. Dox release from DDS3 in the presence of cathepsin B was studied by kinetics measurement based on the fluorescent property of Dox. The cytotoxicity of DDS1 was assessed and found to be non-toxic. Cellular internalization and colocalization studies of all the 3 systems were carried out by flow cytometry and confocal microscopy utilizing cathepsin B-expressing HeLa cells. DDS1 and DDS3 revealed significant localization within the lysosomes, in contrast to DDS2 (control). The doxorubicin-conjugated carrier, DDS3, demonstrated significant cytotoxic effect when compared to free Dox by MTT assay and also by flow cytometric analysis. The targeted approach with DDS3 is expected to be promising, because it is indicated to be advantageous over free Dox, which possesses dose-limiting toxicity, posing risk of injury to normal tissues. This journal is the Partner Organisations 2014.
The Wittig bioconjugation of maleimide derived, water soluble phosphonium ylides to aldehyde-tagged proteins
Asbjarnarson, Arni,Gudjonsson, Thorarinn,Hartmann, Rafael W.,Helgudottir, Hildur Run,Lehmann, Fredrik,Nilvebrant, Johan,Nygren, Per-?ke,Odell, Luke R.,Pijnappel, Matthijs,Traustadottir, Gunnhildur Asta
supporting information, p. 10417 - 10423 (2021/12/17)
Herein we disclose the transformation of maleimides into water-soluble tris(2-carboxyethyl)phosphonium ylides and their subsequent application in the bioconjugation of protein- and peptide-linked aldehydes. The new entry into Wittig bioconjugate chemistry proceeds under mild conditions and relies on highly water soluble reagents, which are likely already part of most biochemists' inventory. This journal is
BIOLOGICAL MATERIALS AND USES THEREOF
-
Page/Page column 64, (2016/06/06)
The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5: 1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.
